ORKA Stock Forecast & Price Target

Oruka Therapeutics is attractive fundamentally because ORKA-001 has already shown best-in-class psoriasis efficacy, with PASI 100 rising from 63.5% at 16 weeks to 71.4% at 28 weeks and a favorable safety profile, while its ~100-day half-life supports a potential Q6M to Q12M maintenance regimen that could meaningfully cut injection burden versus Skyrizi. The opportunity is amplified by a large and growing market, as Skyrizi’s annualized revenue run-rate exceeds $22B and its Q3M maintenance leaves room for an injectable that can deliver comparable or better clearance with far fewer doses. Oruka also has a second platform asset in ORKA-002, which showed a 75-80 day half-life, potent IL-17 inhibition, and dosing potential in PsO and HS, adding pipeline depth and longer-term upside across inflammatory diseases.

Oruka Therapeutics is a clinical-stage company with no approved products, so its value depends heavily on unproven ORKA-001 and ORKA-002 advancing through pivotal trials and winning regulatory approval. The cited framework already embeds meaningful execution risk, with only a 75% probability of approval for ORKA-001 and 40% for ORKA-002, despite modeled peak sales of about $2.8B and $2.5B respectively. Beyond clinical uncertainty, it faces capital needs, potential long-term dilution, competitive pressure, and the possibility that regulators demand extra data or narrower labels, any of which could weaken future returns.